Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of arteries, causes pulmonary hypertension — with high accuracy, a study reported. Findings also showed that lung diseases share similar alterations…

The INOpulse portable oxygen provider widened blood vessels, lowered blood pressure and increased exercise capacity in pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to a study. Bellerophon Therapeutics, which developed the device, reported the results at the American Thoracic Society International Conference in Washington. It also discussed plans for…

Bellerophon Therapeutics recently offered an update on the company’s INOpulse system, as part of its first quarter 2017 financial report. The system is in clinical testing as a therapy for three types of pulmonary hypertension. The Phase 3 INOpulse program for pulmonary arterial hypertension (PAH) has been modified to speed up its clinical development.

The INOpulse nitric-oxide dispenser improves respiratory and exercise capacity in patients with difficult-to-treat pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), a Phase 2 trial indicates. Bellerophon Therapeutics, which developed INOpulse, will present the trial results at an  international conference of the American Thoracic Society International Conference in Washington on May 21.

Bellerophon Therapeutics, Inc., announced the enrollment of the first patient with pulmonary arterial hypertension (PAH) in its Phase 3 INOvation-1 clinical study, assessing the efficacy and safety of the next-generation INOpulse delivery system. The portable device is designed to continuously administer inhaled nitric oxide (iNO) to ambulatory patients using a carefully controlled,…

Researchers from Japan described ways to predict the progression and severity of pulmonary hypertension (PH) in people with left heart disease. Their paper, a review of standard and emerging methods for assessing the lung disease, is titled “The Roles of Classic and Current Prognostic Factors in Pulmonary Hypertension Due…

Idiopathic Pulmonary Fibrosis (IPF) refers to the scarring of the interstitium (the supporting framework of the lungs as well as the pulmonary tissues), with fibroblast proliferation, deposition of extracellular matrix and progressing fibrosis of the tissues. It is a debilitating, lethal condition which worsens progressively, leading to…

Boehringer Ingelheim Pharmaceuticals, Inc. and the Pulmonary Fibrosis Foundation (PFF) have announced a five-year partnership in an effort to raise awareness for the disease and provide patients with disease education. Boehringer Ingelheim’s investment will also contribute to research funding of early diagnosis techniques and new therapies. Pulmonary Fibrosis (PF),…

A new study by Romanian and Belgian scientists sheds light on specific conditions associated with pulmonary hypertension (PH), and which of those conditions are associated with a better prognosis for survival. The report, titled “Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study,”appeared in the…

A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating sarcoidosis-associated pulmonary hypertension (SAPH). PAH refers to high blood pressure of the lungs. The condition can occur as a result of several different diseases, including sarcoidosis; a disease…

An international group of researchers are currently recruiting participants for Sanofi’s Phase 2 trial of SAR156597 for the treatment of idiopathic pulmonary fibrosis (IPF). The official title of the trial, which is now listed at ClinicalTrials.gov, is “Efficacy and Safety of SAR156597 in the Treatment of Idiopathic…

Results from a recent study published in the journal Advance Therapy, showed that pirfenidone (known by the brand name Esbriet from Roche) is effective and has a safety profile consistent with those seen in the Phase III clinical study ASCEND for the treatment of IPF. According to…